Collegium Pharmaceutical, Inc. (COLL)Healthcare | Drug Manufacturers - Specialty & Generic | Stoughton, United States | NasdaqGS
34.31 USD
+34.31
(-0.291%)
⇧
(April 20, 2026, 4 p.m.
EDT)
Short-term: ★★★☆☆ | Long-term: ★★★★☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 18, 2026, 10:28 p.m. EDT
Collegium Pharma (COLL) is a high-conviction value play trading at a 5.3x forward P/E with exceptional cash flow, yet traders are pricing in a 30-25 floor via significant put volume, creating a 'value trap' wait-and-see scenario where the long-term fundamentals are negligible versus the short-term pricing of a potential redraw in price. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.166721 |
| AutoETS | 0.166748 |
| MSTL | 0.166958 |
| AutoTheta | 0.172977 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 40% |
| H-stat | 128.67 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.071 |
| Excess Kurtosis | -1.63 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 310.409 |
| Revenue per Share | 24.619 |
| Market Cap | 1,111,883,136 |
| Trailing P/E | 19.83 |
| Forward P/E | 5.37 |
| Beta | 0.77 |
| Profit Margins | 8.05% |
| Website | https://www.collegiumpharma.com |
As of April 18, 2026, 10:28 p.m. EDT: Speculative positioning is mixed but shows more selling pressure than aggressive buying. Call OI is heavily concentrated at higher strikes (35, 40, 45 in June/Datums; 55 in Sep), indicating a tolerance for upside but placing value at 35-55. Conversely, Put flow is surprisingly active, with significant OI at the 25 and 30 strikes in the June expiration, suggesting a stark expectation of downside support or fear of a 30-25 price floor. The disparity between ATM IV and OI suggests limited bullish conviction compared to the hedging activity seen in the 25-30 strike puts.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.275939 |
| Address1 | 100 Technology Center Drive |
| Address2 | Suite 300 |
| All Time High | 50.787 |
| All Time Low | 7.37 |
| Ask | 34.84 |
| Ask Size | 6 |
| Audit Risk | 6 |
| Average Analyst Rating | 1.7 - Buy |
| Average Daily Volume10 Day | 588,480 |
| Average Daily Volume3 Month | 509,465 |
| Average Volume | 509,465 |
| Average Volume10Days | 588,480 |
| Beta | 0.77 |
| Bid | 33.94 |
| Bid Size | 6 |
| Board Risk | 3 |
| Book Value | 9.514 |
| City | Stoughton |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 3 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 34.31 |
| Current Ratio | 1.571 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 35.25 |
| Day Low | 34.25 |
| Debt To Equity | 310.409 |
| Display Name | Collegium Pharmaceutical |
| Earnings Call Timestamp End | 1,772,110,800 |
| Earnings Call Timestamp Start | 1,772,110,800 |
| Earnings Growth | 0.315 |
| Earnings Quarterly Growth | 0.353 |
| Earnings Timestamp | 1,772,112,600 |
| Earnings Timestamp End | 1,778,157,000 |
| Earnings Timestamp Start | 1,778,157,000 |
| Ebitda | 419,164,000 |
| Ebitda Margins | 0.537 |
| Enterprise To Ebitda | 3.911 |
| Enterprise To Revenue | 2.1 |
| Enterprise Value | 1,639,200,640 |
| Eps Current Year | 7.2992 |
| Eps Forward | 6.3926 |
| Eps Trailing Twelve Months | 1.73 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 38.1575 |
| Fifty Day Average Change | -3.8474998 |
| Fifty Day Average Change Percent | -0.10083207 |
| Fifty Two Week Change Percent | 27.593899 |
| Fifty Two Week High | 50.787 |
| Fifty Two Week High Change | -16.476997 |
| Fifty Two Week High Change Percent | -0.3244334 |
| Fifty Two Week Low | 25.865 |
| Fifty Two Week Low Change | 8.445002 |
| Fifty Two Week Low Change Percent | 0.32650307 |
| Fifty Two Week Range | 25.865 - 50.787 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,431,005,400,000 |
| Float Shares | 31,303,903 |
| Forward Eps | 6.3926 |
| Forward P E | 5.3671436 |
| Free Cashflow | 321,544,256 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 423 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,775,001,600 |
| Gross Margins | 0.88863 |
| Gross Profits | 693,638,016 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.0094 |
| Held Percent Institutions | 1.21361 |
| Implied Shares Outstanding | 32,406,969 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Industry Disp | Drug Manufacturers - Specialty & Generic |
| Industry Key | drug-manufacturers-specialty-generic |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. The company's portfolio includes Jornay PM, a central nervous system stimulant prescription medicine that contains methylphenidate HCl for the treatment of attention deficit hyperactivity disorder; Belbuca, a buccal film that contains buprenorphine for severe and persistent pain that requires an extended treatment period; Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone for the management of pain severe enough to require daily; Nucynta ER and Nucynta IR, which are extended-release and immediate-release oral formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. Collegium Pharmaceutical, Inc. was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. The company was incorporated in 2002 and is headquartered in Stoughton, Massachusetts. |
| Long Name | Collegium Pharmaceutical, Inc. |
| Market | us_market |
| Market Cap | 1,111,883,136 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_7490189 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | 62,870,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 1,111,234,967 |
| Number Of Analyst Opinions | 6 |
| Open | 34.3 |
| Operating Cashflow | 329,323,008 |
| Operating Margins | 0.30038 |
| Overall Risk | 2 |
| Payout Ratio | 0.0 |
| Phone | 781 713 3699 |
| Previous Close | 0.0 |
| Price Eps Current Year | 4.7005153 |
| Price Hint | 2 |
| Price To Book | 3.6062646 |
| Price To Sales Trailing12 Months | 1.4244558 |
| Profit Margins | 0.08054 |
| Quick Ratio | 1.359 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 1.66667 |
| Region | US |
| Regular Market Change | 34.31 |
| Regular Market Change Percent | -0.290609 |
| Regular Market Day High | 35.25 |
| Regular Market Day Low | 34.25 |
| Regular Market Day Range | 34.25 - 35.25 |
| Regular Market Open | 34.3 |
| Regular Market Previous Close | 0.0 |
| Regular Market Price | 34.31 |
| Regular Market Time | 1,776,715,201 |
| Regular Market Volume | 338,005 |
| Return On Assets | 0.07269 |
| Return On Equity | 0.23701 |
| Revenue Growth | 0.129 |
| Revenue Per Share | 24.619 |
| Sand P52 Week Change | 0.34445214 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 2 |
| Shares Outstanding | 32,406,969 |
| Shares Percent Shares Out | 0.1707 |
| Shares Short | 5,530,407 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 4,599,035 |
| Short Name | Collegium Pharmaceutical, Inc. |
| Short Percent Of Float | 0.204 |
| Short Ratio | 8.44 |
| Source Interval | 15 |
| State | MA |
| Symbol | COLL |
| Target High Price | 60.0 |
| Target Low Price | 44.0 |
| Target Mean Price | 54.16667 |
| Target Median Price | 56.0 |
| Total Cash | 386,679,008 |
| Total Cash Per Share | 12.178 |
| Total Debt | 936,427,008 |
| Total Revenue | 780,566,976 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | NaN |
| Trailing Eps | 1.73 |
| Trailing P E | 19.83237 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 39.335876 |
| Two Hundred Day Average Change | -5.025875 |
| Two Hundred Day Average Change Percent | -0.12776822 |
| Type Disp | Equity |
| Volume | 338,005 |
| Website | https://www.collegiumpharma.com |
| Zip | 2,072 |